Unlike previous reviews that primarily catalog FAK biology and inhibitor development, this work provides a direct mechanistic comparison between GBM and NF2-mutant meningioma to illustrate how genetic context - not histological grade or target abundance - dictates therapeutic relevance. This evidence concerns the gene NF2 and glioblastoma.